Drug regulator CDSCO flags 205 drug samples as not of standard quality in November

Central and state drug testing laboratories identified substandard and spurious medicines during routine nationwide surveillance

India’s apex drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has flagged 205 drug samples as Not of Standard Quality (NSQ) following nationwide testing carried out in November, according to its latest monthly drug alert.

Of the total samples that failed quality checks, 64 were identified by Central Drugs Laboratories, while 141 were flagged by State Drugs Testing Laboratories. The findings form part of routine regulatory surveillance undertaken jointly by central and state authorities to monitor the quality of medicines available in the market.

The CDSCO stated that the list of NSQ and spurious drugs is uploaded on its official portal every month as part of its transparency and compliance measures. Officials clarified that a drug sample is classified as NSQ when it fails to meet one or more prescribed quality parameters during laboratory testing.

Such failure is limited to the specific batch tested and does not automatically raise concerns about other batches or similar products available in the market.

In addition to substandard drugs, regulators also identified two spurious drug samples in November from the North Zone laboratory in Ghaziabad. These were found to have been manufactured by unauthorised entities using brand names owned by other companies.

The matter is currently under investigation, and regulatory action will be initiated in accordance with the Drugs and Cosmetics Act and its associated rules.

Health officials emphasised that the ongoing identification and removal of NSQ and spurious medicines is a continuous exercise carried out in coordination with state drug regulators to safeguard public health and maintain the integrity of the pharmaceutical supply chain.

The November figures show a marginal decline compared to October, when a total of 211 drug samples were declared NSQ. At that time, Central Drugs Laboratories had identified 63 substandard samples, while State Drugs Testing Laboratories had flagged 148.

Related Posts

Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says

US President Donald Trump on Monday said nine pharmaceutical manufacturers, including Sun Pharma, have reached agreements with his administration to lower prescription drug prices for Americans in line with the…

FIR against 22 foreign medical graduates for uploading fake docus on Maharashtra Medical Council portal to obtain temporary registration without clearing screening test

Mumbai: The Maharashtra Nodal Cyber Police have registered an FIR against 22 foreign medical graduates for allegedly uploading fake and suspicious documents on Maharashtra Medical Council (MMC) portal to obtain…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says

Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says

FIR against 22 foreign medical graduates for uploading fake docus on Maharashtra Medical Council portal to obtain temporary registration without clearing screening test

FIR against 22 foreign medical graduates for uploading fake docus on Maharashtra Medical Council portal to obtain temporary registration without clearing screening test

FUJIFILM India is zeroing in on Indian Gut with Advanced Therapeutic Endoscopy

FUJIFILM India is zeroing in on Indian Gut with Advanced Therapeutic Endoscopy

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government